08:00 , Jan 9, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Melanoma MAP kinase 1 (MAPK1; ERK-2); MAPK3 (ERK-1) Studies in human tissue and cell culture suggest inhibiting...
08:00 , Jan 9, 2014 |  BC Innovations  |  Targets & Mechanisms

The next battle line against melanoma

Boston and Los Angeles researchers have painted the best portrait to date of the resistance mutations that arise from treating melanoma with BRAF and MEK inhibitors.1-4 Although the resistance pathways were known, the new information...
07:00 , Apr 16, 2012 |  BC Week In Review  |  Clinical News

Aeterna Zentaris preclinical data

In mice, once-daily 60 mg/kg oral AEZS-136 given for 28 days in a model of colon cancer and once-daily 90 mg/kg oral AEZS-136 given for 22 days in a model of endometrial cancer led to...